DaVita Inc. (DVA)
Best Growth Stocks to Buy for May 21st
DVA, TAL, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 21, 2026.
Best Value Stocks to Buy for May 19th
UVE, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 19, 2026.
Best Growth Stocks to Buy for May 19th
DVA, PBI, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 19, 2026.
Best Growth Stocks to Buy for May 14th
NXST, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 14th, 2026.
DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
DaVita HealthCare (DVA) Is Up 30.99% in One Week: What You Should Know
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Surging Earnings Estimates Signal Upside for DaVita HealthCare (DVA) Stock
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Value Investors Buy DaVita (DVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita: Improved Volumes And Tech In Focus (Rating Upgrade)
DaVita Inc. is upgraded to a Buy following robust Q1 results and a 23% post-earnings stock surge. DVA's Q1 non-GAAP EPS of $2.87 beat consensus, with revenue up 6% year-over-year and management raising guidance. Mid-teens EPS growth is expected through 2026, with a 10%+ FCF yield and a modest P/E ratio supporting valuation.
